Acarbose vs Miglitol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Alpha-glucosidase · full Type 2 Diabetes pipeline

Acarbose · Precose / Glucobay

Rights held by Bayer; US product discontinued

Approved in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Miglitol · Glyset

Rights held by Bayer and partners

US approval withdrawn in Type 2 Diabetessmall molecule
Partial signal

NCT00213070 · Phase 3 · completed

The study was randomized and double-blind, but the registry does not clearly identify a comparator arm, sample size, or primary endpoint. Because no results are posted, it is not possible to determine whether the primary glycemic endpoint was met.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAcarboseMiglitol
HbA1c, change-0.8% vs -0.1%−0.6 vs placebowk 24 · n 185NCT01177384—Not posted · NCT00380822
Body weight, change (kg)—Not posted · NCT01010100—Not posted · NCT00380822
HbA1c below 7%—Not posted · NCT01010100—Not posted · NCT00380822
Fasting plasma glucose, change-1.0 vs -0.2−0.8 vs placebowk 24 · n 187NCT01177384—Not posted · NCT00380822
3-point MACE (% with event)—Not posted · NCT01010100—Not posted · NCT00380822

HbA1c, change

Acarbose
-0.8% vs -0.1%−0.6 vs placebowk 24 · n 185NCT01177384
Miglitol
—Not posted · NCT00380822

Body weight, change (kg)

Acarbose
—Not posted · NCT01010100
Miglitol
—Not posted · NCT00380822

HbA1c below 7%

Acarbose
—Not posted · NCT01010100
Miglitol
—Not posted · NCT00380822

Fasting plasma glucose, change

Acarbose
-1.0 vs -0.2−0.8 vs placebowk 24 · n 187NCT01177384
Miglitol
—Not posted · NCT00380822

3-point MACE (% with event)

Acarbose
—Not posted · NCT01010100
Miglitol
—Not posted · NCT00380822
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Miglitol: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Acarbose: 3 of 4 rows · Miglitol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAcarbose
Dropout rate
7.3%a
NCT01177384 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
3.1%a
NCT01177384 · Phase 3 · registry result, not featured evidence
Serious AEs
5.2%a
NCT01177384 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Acarbose

HbA1c -0.76% (n=185) vs -0.14% (n=180) placebo @ 24wk
absolute change · percentage points
NCT01177384 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -0.99 vs -0.19 placebo mmol/L @ 24wk
absolute change · mmol/L
NCT01177384 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.9 mg/dL as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acarbose's landscape · Miglitol's landscape